The AVID-CC trial will test the anti-tumor necrosis factor (anti-TNF) drug and will be aimed at treating people in the community, especially in care homes. It will enroll up to 750 patients from community care settings throughout the UK.
Oxford to study popular prescription drug as potential COVID-19 treatment
By REUTERS
05/06/2024 01:52 PM
By REUTERS
05/06/2024 01:49 PM
By REUTERS
05/06/2024 10:36 AM
By WALLA!
05/06/2024 03:47 AM
By WALLA!
05/06/2024 02:01 AM
By REUTERS
05/06/2024 12:54 AM
By REUTERS
05/05/2024 06:39 PM
By REUTERS
05/05/2024 04:55 PM
By REUTERS
05/05/2024 04:06 PM